Pfizer Brings Prevenar 13 To India But Lack Of Immunization Awareness Remains Concern
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Pfizer's ability to propel growth at the back of Prevenar 13 - its latest-generation vaccine to protect children from a number of strains that cause pneumococcal diseases - could be gauged from its high-profile launch in India July 8
You may also be interested in...
China Overlooks Pneumonia Threat; Pfizer Sees Greater Opportunity For Prevenar In India
HONG KONG - Pneumonia is one of China's great killers but it only gets peripheral attention from health authorities, which presents a challenge for companies like Pfizer that are trying to draw interest for vaccines in emerging markets
China Overlooks Pneumonia Threat; Pfizer Sees Greater Opportunity For Prevenar In India
HONG KONG - Pneumonia is one of China's great killers but it only gets peripheral attention from health authorities, which presents a challenge for companies like Pfizer that are trying to draw interest for vaccines in emerging markets
Pfizer Vaccines President Mark Swindell On Prevenar 13 in Developing Countries And Emerging Markets: An Interview With PharmAsia News
Pfizer and GlaxoSmithKline attracted attention earlier this year while finalizing an agreement with the public-private GAVI Alliance to bring the newest pneumococcal vaccines - Prevenar 13 and Synflorix, respectively - to developing countries. Pfizer announced in August that the World Health Organization granted prequalification status to Prevenar 13, a condition for the drug to be used by United Nations agencies, including UNICEF. Pfizer Vaccines President Mark Swindell spoke with PharmAsia News following the WHO announcement to discuss the company's vaccine strategy in emerging markets.